Sinclair Research Appoints Jeffrey Klein as Director of Toxicology and Dermatology
COLUMBIA, Mo.--(BUSINESS WIRE)--Jun 13, 2018--Sinclair Research, one of the nation’s leading providers of preclinical services, is pleased to announce new scientific leadership with the arrival of Jeffrey Klein, Ph.D., DABT, as director of toxicology and dermatology. In this newly created role, Klein will be responsible for the company’s scientific direction in toxicology and dermatology services and their operational processes. He will drive the growth of Sinclair’s business model and foster positive relationships with new and current customers.
Klein joins Sinclair Research from EP Technologies LLC in Akron, Ohio, where he directed preclinical research including discovery, toxicology and management of active transdermal technology. He held a similar position at Noven Pharmaceuticals working with passive transdermal technology. With more than 15 years of industry experience, including serving as a study director at Ricerca Biosciences (now Concord Biosciences), Klein is an accomplished toxicology and drug development professional with extensive expertise in both technical study management and customer service. His preclinical knowledge and experience from the pharmaceutical and contract research organization industries will be of significant value to Sinclair and all its customers.
“Jeff is an exciting new addition to the Sinclair research staff. In addition to his extensive experience in general toxicology and program management, he significantly enhances our scientific depth in the area of dermatology. Jeff will be an invaluable resource for clients developing products in this area,” said G. Alex Wakefield, Sinclair’s vice president of research and operations.
About Sinclair Research Sinclair Research Center, a preclinical contract research organization (CRO) established in 1964, offers animal efficacy models, IND enabling toxicology services and research capabilities to animal health and medical device companies. Our clients include large, mid-tier, small and startup companies in both human and animal health markets. With more than 50 years’ experience, Sinclair is the undisputed expert in all breeds of miniature swine. In addition, we manage many standing animal colony models including diabetes, wound healing, irritable bowel disease and general PK, and we have developed and maintain our own unique research breed of mini-swine, “The Sinclair Pig.”
View source version on businesswire.com:https://www.businesswire.com/news/home/20180613005174/en/
CONTACT: For Sinclair Research
Lea Studer, 402-366-1752
KEYWORD: UNITED STATES NORTH AMERICA MISSOURI
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Sinclair Research
Copyright Business Wire 2018.
PUB: 06/13/2018 08:00 AM/DISC: 06/13/2018 08:01 AM